API
< Back to all clusters
[BUSINESS] · United States · 2 sources

started · updated

Acadia Pharmaceuticals advances remlifanserin after mixed Phase II trial results

Acadia Pharmaceuticals reported top-line results from the Phase II portion of its RADIANT clinical program, which evaluates remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

The 60 mg once-daily dose narrowly missed the primary endpoint of statistical significance on the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions (SAPS-H+D) total score, yielding a p-value of 0.0603. However, the dose showed nominal statistical significance on a key secondary endpoint, the Clinical Global Impression-Severity scale (CGI-S-ADP), with a p-value of 0.0077. The 30 mg dose showed almost no significant improvement.

Despite the primary endpoint miss, the drug demonstrated a safety and tolerability profile comparable to a placebo. Acadia plans to proceed with two ongoing Phase III trials, focusing on the 60 mg dose and removing the 30 mg dose from its development strategy. Following the announcement, the company's stock experienced volatility, and some analysts, such as those at Citizens JMP, reduced their price targets.

Entities

Acadia Pharmaceuticals